SEER Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

Q4 Revenue: $4.2 million, a 5% increase year-over-year from $4 million in Q4 2024. Excluding related party revenue, growth was 16%.
Full Year Revenue: $16.6 million, a 17% increase from $14.2 million in 2024. Excluding related party revenue, total revenue grew approximately 33%.
Gross Profit: Q4 gross profit was $2.2 million (52% margin), up from $2 million (51% margin) in Q4 2024. Full year gross profit was $8.5 million (51% margin), compared to $7.1 million (50% margin) in 2024.
Operating Expenses: Q4 operating expenses were $19.6 million, down 23% from $25.5 million in Q4 2024. Full year operating expenses decreased by 19% to $86.5 million.
Net Loss: Q4 net loss was $16 million, improving from $21.7 million in Q4 2024. Full year net loss was $73.6 million, down from $86.6 million in 2024.
Cash Position: Ended 2025 with approximately $241 million in cash and equivalents.

2. Strategic Updates and Business Highlights

Installed Base Growth: Increased by 67% to 82 instruments by year-end 2025, with 60% from the Strategic Instrument Placement Program (SIPP).
Consumable Kit Volume: Grew by 69% year-over-year, indicating higher utilization of the Proteograph platform.
Publications: Cumulative publications nearly doubled to 70, showcasing the increasing validation and interest in Seer’s technology.
PrognomIQ Launch: Launched ProVue Lung, an early lung cancer detection test developed using Seer’s technology.
Partnerships: Continued collaboration with Thermo Fisher Scientific to co-market the Proteograph Product Suite.

3. Forward Guidance and Outlook

2026 Revenue Guidance: Expected to be between $16 million and $18 million, reflecting a cautious outlook due to ongoing pressures on customer spending, particularly related to NIH funding.
Market Dynamics: Anticipated continued challenges in securing new project funding and instrument placements, with potential upside from additional population-scale studies not included in guidance.

4. Bad News, Challenges, or Points of Concern

Funding Environment: Ongoing uncertainty around NIH funding has led to delayed purchases from customers, impacting revenue expectations.
Sales Cycle Lengthening: Customers are hesitant to commit to new expenditures without secured funding, leading to elongated sales cycles.
Revenue Volatility: Small revenue numbers can lead to significant fluctuations in quarterly results, making financial projections challenging.
Competitive Landscape: Customers face a choice between established targeted approaches and Seer's untargeted proteomics, which may slow adoption despite growing evidence of Seer’s value.

5. Notable Q&A Insights

Customer Feedback: Customers are increasingly recognizing the value of untargeted proteomics, as evidenced by the growing number of publications and successful studies.
Growth Potential: Management expressed optimism about future growth, suggesting that once the scientific community fully embraces the benefits of Seer's technology, revenue could see substantial increases.
Conservative Guidance: Management acknowledged the momentum but opted for a conservative revenue forecast due to uncertainties in the funding environment and customer behavior.

Overall, while SEER demonstrated solid growth in installed base and revenue, it faces significant challenges related to funding uncertainties and competitive pressures that could impact future performance.

SEER — Seer, Inc.